First U.S. Patient Enrolls in Groundbreaking Clinical Trial at Jefferson by unknown
 The STABLE™ trial is 
an important milestone 
in the development of 
novel, minimally invasive 
treatments for thoracic  
aortic dissections
THOMAS JEFFERSON UNIVERSITY AND HOSPITALS
When James Blassingame, 79, and his 
wife returned home from church one 
Sunday, he bent down and could not 
stand back up, doubled over in pain. 
He was rushed to a local hospital, 
where Joseph Lombardi, MD, director 
of the new Jefferson Aortic Center and 
Associate Professor of Surgery was 
called for consultation. Dr. Lombardi 
diagnosed Mr. Blassingame with a  
Type B dissection of his thoracic aorta. 
Mr. Blassingame was transferred to the 
Thomas Jefferson University Hospital for 
surgery where he became the first patient 
in the U.S. to enroll in the STABLE™ 
Aortic Dissection clinical trial. “The 
STABLE trial is an important milestone 
in the development of novel, minimally 
invasive treatments for thoracic aortic 
dissections,” explains Dr. Lombardi,  
who is global Principal Investigator (PI) 
of the study. 
Mr. Blassingame, a retired staffing 
specialist for the federal government, 
is grandfather to 18 grandchildren and 
seven great grandchildren. “At my age, 
I was concerned about having any kind 
of surgery,” he recalls. “I thought I could 
just do without it, especially knowing 
that open surgery could be fatal. But 
my daughter, who is a licensed nurse 
practitioner, explained how important 
and non-invasive this surgery was, 
and how it would really help to reduce 
the risks of complications or worse.” 
Performing Mr. Blassingame’s surgery 
with Dr. Lombardi was Robert A. 
Larson, MD, Assistant Professor of 
Surgery, who serves as the site PI for 
the STABLE™ trial. This trial and other 
new programs at Jefferson led to the 
expansion and renaming of the Division 
of Vascular and Endovascular Surgery.
Endovascular surgery directs therapy 
through catheters and wires placed 
within the blood vessels. The stents hold 
open the wall of the weakened vessel, 
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Mr. James Blassingame, the first patient in the U.S. to enroll in the STABLE™ Aortic Dissection  
clinical trial, contemplates the morning from his front porch several months after his operation.
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James Blassingame was a perfect 
candidate for participation in the 
STABLE™ Aortic Dissection clinical 
trial. Given the combination of his  
age, medical history, and what we  
were able to learn from our pre-surgical 
vascular mapping, we knew that we 
could successfully treat him with the 
Cook Zenith™ Dissection Endovascular 
System. The technology we now have 
enables us to treat patients like James 
in a way that radically reduces risks and 
decreases the recovery period. 
In Mr. Blassingame’s case, our three-
dimensional TeraRecon workstation 
was critical in determining if he was 
anatomically suitable for endovascular 
surgery. We used the 3D imaging to 
measure the size of the vessel and to 
determine how much to treat. It is the 
ultimate planning tool—enabling you 
to visualize the procedure, select the 
right devices, and see in advance exactly 
where the weakened vessel begins and 
ends. Once planned, the operation 
was performed with state of the art 
equipment in our new endovascular 
operating suite.
Joseph V. Lombardi, MD, (shown left) 
and Robert A. Larson, MD
 
The Surgeons Speak
and the endovascular grafts – fabric 
tubes used to make a new path for the 
blood to flow – are placed inside the 
vessel. This minimally invasive method 
spares patients the trauma and risk of 
open surgery, decreases recovery time, 
and improves quality of life following  
the procedure.
“The STABLE™ trial will significantly 
help treat a condition that affects tens of 
thousands of people just like James every 
year,” says Dr. Lombardi. “This truly is a 
remarkable, lifesaving advancement.”  
 
For more information about 
endovascular surgery visit:  
www.jeffersonhospital.org/aortic 
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